- Home
- Results news
- Paushak
- Q2 FY27 results
Paushak Q2 FY27 results: net profit up 56.9% to ₹13.51 crore, revenue up 52.0%
Paushak Limited reported standalone results for Q2 FY27, with revenue of ₹89.32 crore and net profit of ₹13.51 crore for the July–September 2026 quarter. Revenue rose 52.0% from Q2 FY26 and 6.9% from Q1 FY27, while profit after tax was higher year on year but lower sequentially.
Key points
- Revenue was ₹89.32 crore in Q2 FY27, up 52.0% from ₹58.78 crore in Q2 FY26 and 6.9% from ₹83.55 crore in Q1 FY27.
- EBITDA was ₹26.36 crore, with an EBITDA margin of 29.5%, compared with ₹14.80 crore and 25.2% in Q2 FY26.
- Net profit was ₹13.51 crore, up 56.9% from ₹8.61 crore in Q2 FY26 but down 10.5% from ₹15.10 crore in Q1 FY27.
- Basic EPS was ₹5.48, compared with ₹27.94 in Q2 FY26 and ₹6.13 in Q1 FY27.
- The results were standalone and covered one reportable segment, Speciality Chemicals.
How did Paushak perform in Q2 FY27?
Paushak reported standalone revenue from operations of ₹89.32 crore in Q2 FY27, compared with ₹58.78 crore in Q2 FY26 and ₹83.55 crore in Q1 FY27. The year-on-year increase was 52.0%, while the sequential increase was 6.9%. Total income was ₹91.35 crore, against ₹59.82 crore a year earlier and ₹86.69 crore in the previous quarter.
EBITDA was ₹26.36 crore in Q2 FY27, up 78.1% from ₹14.80 crore in Q2 FY26 and 2.8% from ₹25.65 crore in Q1 FY27. The EBITDA margin rose 4.3 percentage points year on year to 29.5%, but fell 1.2 percentage points from 30.7% in the previous quarter.
Profit before tax was ₹18.60 crore, compared with ₹11.34 crore in Q2 FY26 and ₹19.02 crore in Q1 FY27. Net profit was ₹13.51 crore, up 56.9% from ₹8.61 crore a year earlier but down 10.5% from ₹15.10 crore in the previous quarter. Basic EPS was ₹5.48, versus ₹27.94 in Q2 FY26 and ₹6.13 in Q1 FY27; the company’s filing states that previous-period EPS was restated for the share subdivision and bonus shares.
| ₹ crore | Q2 FY27 | Q1 FY27 | Q2 FY26 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 89.32 | 83.55 | 58.78 | +52.0% | +6.9% |
| Other income | 2.03 | 3.15 | 1.05 | +93.3% | −35.6% |
| Total expenses | 72.75 | 67.68 | 48.48 | +50.1% | +7.5% |
| EBITDA | 26.36 | 25.65 | 14.80 | +78.1% | +2.8% |
| EBITDA margin | 29.5% | 30.7% | 25.2% | +4.3 pp | −1.2 pp |
| Profit before tax | 18.60 | 19.02 | 11.34 | +64.0% | −2.2% |
| Tax | 5.08 | 3.91 | 2.73 | +86.1% | +29.9% |
| Net profit | 13.51 | 15.10 | 8.61 | +56.9% | −10.5% |
| EPS (₹) | 5.48 | 6.13 | 27.94 | −80.4% | −10.6% |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in Paushak's costs and profit?
Total expenses rose to ₹72.75 crore in Q2 FY27 from ₹48.48 crore in Q2 FY26, an increase of ₹24.27 crore, or 50.1%. Cost of materials consumed increased by ₹13.26 crore, or 86.3%, to ₹28.63 crore, while depreciation and amortisation increased by ₹3.97 crore, or 88.8%, to ₹8.44 crore.
Finance costs increased by ₹1.31 crore, or 3275.0%, to ₹1.35 crore from ₹0.04 crore in Q2 FY26. Other expenses rose by ₹1.02 crore, or 5.4%, to ₹19.78 crore. Employee benefits expense declined by ₹0.67 crore, or 6.9%, to ₹9.09 crore. Other income rose by ₹0.98 crore, or 93.3%, to ₹2.03 crore.
Tax expense increased by ₹2.35 crore, or 86.1%, to ₹5.08 crore from ₹2.73 crore in Q2 FY26. There was no exceptional item in either quarter. The filing does not state a reason for the year-on-year movements in costs, other income or tax.
| ₹ crore | Q2 FY27 | Q2 FY26 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 28.63 | 15.37 | +13.26 | +86.3% |
| Employee cost | 9.09 | 9.76 | −0.67 | −6.9% |
| Finance costs | 1.35 | 0.04 | +1.31 | +3275.0% |
| Depreciation | 8.44 | 4.47 | +3.97 | +88.8% |
| Other expenses | 19.78 | 18.76 | +1.02 | +5.4% |
| Total expenses | 72.75 | 48.48 | +24.27 | +50.1% |
| Other income | 2.03 | 1.05 | +0.98 | +93.3% |
| Tax | 5.08 | 2.73 | +2.35 | +86.1% |
Source: Company's results filing (XBRL).
How did the first half of FY27 go?
For H1 FY27, Paushak reported standalone revenue of ₹172.87 crore, compared with ₹114.66 crore in H1 FY26, an increase of ₹58.21 crore or 50.8%. Total income was ₹178.05 crore, up ₹60.46 crore or 51.4% from ₹117.59 crore in the year-ago period.
Profit before tax rose to ₹37.61 crore from ₹26.97 crore in H1 FY26, an increase of ₹10.64 crore or 39.5%. Profit after tax was ₹28.62 crore, compared with ₹20.65 crore, up ₹7.97 crore or 38.6%. Basic EPS for H1 FY27 was ₹11.61.
| ₹ crore | H1 FY27 | H1 FY26 | Change |
|---|---|---|---|
| Revenue from operations | 172.87 | 114.66 | +50.8% |
| Profit before tax | 37.61 | 26.97 | +39.5% |
| Net profit | 28.62 | 20.65 | +38.6% |
| EPS (₹) | 11.61 | 66.99 | −82.7% |
Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
At 30 September 2026, total assets were ₹684.5 crore, compared with ₹659.94 crore at 31 March 2026. Total equity rose to ₹516.6 crore from ₹491.12 crore, while borrowings fell to ₹67.5 crore from ₹76.94 crore. Cash and cash equivalents were ₹2.72 crore, compared with ₹0.02 crore at the previous balance-sheet date.
Inventories were ₹36.48 crore against ₹36.64 crore on 31 March 2026. Trade receivables rose to ₹77.18 crore from ₹54.86 crore, while trade payables increased to ₹38.7 crore from ₹30.67 crore. For H1 FY27, net cash from operating activities was ₹40.72 crore, compared with ₹24.68 crore in H1 FY26.
Investing cash flow was negative ₹19.85 crore in H1 FY27, compared with negative ₹52.53 crore in H1 FY26, while financing cash flow was negative ₹18.17 crore against positive ₹28.02 crore. Capital expenditure was ₹10.83 crore, compared with ₹63.64 crore in the year-ago period. The filing reported closing cash of ₹2.72 crore.
| ₹ crore | As of 30 September 2026 | As of 31 March 2026 |
|---|---|---|
| Total assets | 684.50 | 659.94 |
| Total equity | 516.60 | 491.12 |
| Borrowings | 67.50 | 76.94 |
| Cash and equivalents | 2.72 | 0.02 |
| Inventories | 36.48 | 36.64 |
| Trade receivables | 77.18 | 54.86 |
Source: Company's results filing (XBRL).
| ₹ crore | H1 FY27 | H1 FY26 |
|---|---|---|
| Cash from operations | 40.72 | 24.68 |
| Cash from investing | −19.85 | −52.53 |
| Cash from financing | −18.17 | 28.02 |
| Capital expenditure | 10.83 | 63.64 |
Source: Company's results filing (XBRL).
How has Paushak done over the last 8 quarters?
Paushak’s quarterly revenue increased in each of the last three quarters on a year-on-year basis, and profit also rose year on year in each of those quarters. Revenue reached ₹89.32 crore in Q2 FY27, the highest level in the eight-quarter series shown, after ₹83.55 crore in Q1 FY27 and a low of ₹48.8 crore in Q3 FY26.
Net profit in the series ranged from ₹6.17 crore in Q3 FY26 to ₹15.26 crore in Q3 FY25. Q2 FY27 profit was ₹13.51 crore, below Q1 FY27’s ₹15.10 crore. The EBITDA margin was 29.5% in Q2 FY27, below the 31.9% peak in Q1 FY26 and above the 23.4% low in Q3 FY26.
How did Paushak shares react?
The filing was released after market hours, and the shares fell 5.4% within five minutes, 6.5% within 15 minutes and 7.2% within 30 minutes of the filing appearing. On the reaction day, the stock closed 19.2% lower from the previous close. By the next day’s close, it was down 22.1% from the pre-results close, and by five sessions, it was down 24.4%.
The Specialty Chemicals industry median fell 1.8% on the reaction day, 4.8% by the next day and 7.1% by five sessions. Paushak therefore underperformed the industry median by 17.4 percentage points on the reaction day, 17.2 percentage points by the next day and 17.3 percentage points by five sessions. Earlier reaction-day moves were 4.8% on 30 July 2026, 8.3% on 5 May 2026 and negative 4.7% on 27 January 2026.
| After the filing | Stock | Specialty Chemicals median |
|---|---|---|
| 5 minutes | −5.4% | |
| 15 minutes | −6.5% | |
| 30 minutes | −7.2% | |
| Reaction day | −19.2% | −1.8% |
| Next day | −22.1% | −4.8% |
| 5 days | −24.4% | −7.1% |
Minutes are measured from the price when the filing appeared; days from the previous close. Source: MarketPing price-reaction measurement.
| Results filed on | Stock on the reaction day |
|---|---|
| 30 July 2026 | +4.8% |
| 5 May 2026 | +8.3% |
| 27 January 2026 | −4.7% |
Source: MarketPing price-reaction measurement.
How did other Specialty Chemicals companies do?
Among 51 other Specialty Chemicals companies compared for the quarter, the median revenue growth was 28.1%. Of these peers, 38 grew more slowly than Paushak and 13 grew faster than Paushak. Profit was higher for 41 peers, based on a profit comparison involving 47 companies.
| Paushak revenue growth (YoY) | +52.0% |
|---|---|
| Median of 51 other Specialty Chemicals companies | +28.1% |
| Companies with slower revenue growth than Paushak | 38 of 51 |
| Companies with faster revenue growth than Paushak | 13 of 51 |
| Companies whose net profit rose | 41 of 47 |
Source: Filed results (XBRL) of the industry's companies.
Quick answers
What was Paushak's revenue in Q2 FY27?
Revenue from operations was ₹89.32 crore, up 52.0% from ₹58.78 crore in Q2 FY26 (standalone).
Did Paushak make a profit in Q2 FY27?
Yes. Net profit was ₹13.51 crore, against a net profit of ₹8.61 crore in Q2 FY26.
What was Paushak's EPS in Q2 FY27?
Basic earnings per share were ₹5.48, against ₹27.94 in Q2 FY26.
How did Paushak shares react to the Q2 FY27 results?
On the reaction day the stock moved −19.2% from the previous close; the median Specialty Chemicals stock moved −1.8%.
When did Paushak announce its Q2 FY27 results?
On 16 October 2026, in a filing to the BSE.
Sources
- Board Meeting Intimation for Board Meeting To Consider Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September, 2026. (BSE, 8 October 2026) · PDF
- Board Meeting Outcome for Outcome Of Board Meeting (BSE, 16 October 2026) · PDF
- Unaudited Financial Results Of The Company For The Quarter And Half Year Ended On 30Th September, 2026. (BSE, 16 October 2026) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.